Industry News
Pharmaceutical Industry News
Most Patients Keep Weight Off With Fewer GLP-1 Shots, Study Finds
In a recent review, a small group of patients received the injections less frequently but still maintained weight loss and health benefits.
Eli Lilly has officially launched…
Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after teasing the rollout late last year.
Collegium Pharmaceutical has…
Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder.
BioDuro, headquartered in…
BioDuro, headquartered in California, has set up a new joint venture with Taiwan drug ingredients manufacturer, Cenra API Solutions. The new enterprise will see Cenra’s commercial-scale facility in Taipei folded into BioDuro’s production network.
The company has been pressing the…
The company has been pressing the FDA to hold a formal hearing on its proposed jet lag label expansion for Hetlioz since it was first snubbed way back in 2019.
The primary growth drivers in…
The primary growth drivers in Bayer’s pharma sector—Nubeqa and Kerendia—are performing even better than the company anticipated and their momentum is expected to continue in 2026. But that won’t lead to growth of Bayer’s pharma
Not long after Novo Nordisk…
Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its Wegovy pill, another of the Danish drugmaker’s GLP-1 ads is in the regulator’s
Traditional feasibility misses…
Traditional feasibility misses critical signals about patient reality. Patient journey intelligence reveals them, making truly patient-centric trials possible.
Moderna will pay $950 million…
Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roivant subsidiary Genevant and infectious disease biotech Arbutus back in 2022.
Patient Advocate Foundation and…
Patient Advocate Foundation and PAN Foundation announce merger, creating a single destination for patients facing access and affordability challenges.
NoA Health has appointed Louisa…
NoA Health has appointed Louisa Lee as CEO, putting the former Novo Nordisk and Pfizer employee at the head of the creative agency’s push to take its business global.
Sanofi is betting $1.53 billion on…
Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s hematology and immunology pipeline.
Trump, Iran and a Host of Questions
Questions about the future of the attack on Iran, and other reader perspectives. Also: Drug ads as a resource for patients.
In the letters sent to 30…
In the letters sent to 30 different telehealth companies that market compounded versions of GLP-1 drugs, the agency threatened "legal action without further notice."
Pfizer CEO Albert Bourla, Ph.D.,…
Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp criticism of the FDA’s Vinay Prasad, M.D., and his performance as the chief of the Center for Biologics Evaluation and Research, which regulates vaccines in
Amid an influx of U.S….
Amid an influx of U.S. investments, geopolitical uncertainties support the need for manufacturing projects in other regions, IDA Ireland's Rory Mullen told Fierce.
Dr. McDreamy has signed onto yet…
Dr. McDreamy has signed onto yet another cancer awareness initiative. “Grey’s Anatomy” star Patrick Dempsey, who has worked with Amgen since 2007 and joined forces with Pfizer in 2024, is now collaborating with cancer test
The FDA is providing more insight…
The FDA is providing more insight into the rejections it recently handed two pharma giants, publishing the complete response letters (CRLs) sent to AstraZeneca and GSK that highlight shortfalls in the data included in their
Novo will invest 432 million euros…
Novo will invest 432 million euros ($501 million) to add a new tableting plant at its facility in Athlone, Ireland, the company said in a March 2 press release. The expansion will equip the Athlone
Esperion has acquired Corstasis…
Esperion has acquired Corstasis Therapeutics and its nasal spray Enbumyst, which was approved by the FDA six months ago. Esperion paid $75 million upfront and earmarked $180 million for potential milestones while agreeing to pay